Right on the heels of a PhIII failure, Merck neuroscience doubles down with a new drug targeting tau
Merck isn’t letting its first big Phase III failure in Alzheimer’s get in the way of its ambitions in the field. The pharma giant …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
